File size: 1,514 Bytes
1ca8459 | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 | # Scientific Scope
## What This Resource Does
This benchmark integrates evidence-synthesis scores, target tractability, omics/pathway recurrence, ChEMBL compound activity, simple drug-likeness heuristics, Human Protein Atlas cell-type context, stem-cell validation mappings, and knowledge-graph exports for Parkinson's disease target-to-intervention research.
## What It Does Not Do
It does not prove that any drug, supplement, diet, or lifestyle change prevents or cures Parkinson's disease. It does not recommend off-label clinical use. It does not replace systematic review, pharmacology review, toxicology, cellular validation, animal studies, or clinical trials.
## Appropriate Uses
- benchmarking target-prioritisation methods;
- identifying candidate targets for iPSC-derived dopaminergic-neuron experiments;
- comparing drug-repurposing heuristics;
- teaching translational bioinformatics workflows;
- generating hypotheses for independent validation.
## Highest-Priority Validation Direction
The most defensible next experiments are target-module validation studies that connect reproducible PD biology to feasible assays:
- lysosome/autophagy and GBA1/LRRK2 biology in patient-derived dopaminergic neurons;
- mitochondrial stress and PINK1/Parkin-axis readouts;
- alpha-synuclein aggregation and clearance assays;
- inflammatory co-culture systems for microglial or cytokine-mediated effects;
- metabolic/GLP-1 signalling assays as disease-modification hypotheses, not clinical recommendations.
|